Locations
Newton, MA, USA · Newton, NJ, USA
industry
Biotechnology · Biotechnology Research · Clinical Trials · Life Science · Oncology · Therapeutics
Size
51 - 200 employees
Stage
Other
founded in
2015
About

Abcuro is a clinical-stage biotechnology company developing antibody-based therapies for autoimmune diseases and cancer. The company focuses on targeting highly cytotoxic T cells that contribute to tissue damage and disease progression. Its pipeline includes ulviprubart, a monoclonal antibody designed to selectively deplete cytotoxic T cells while preserving other immune cells. Abcuro is evaluating its therapies in clinical studies for conditions including inclusion body myositis and other immune-mediated diseases, as well as potential applications in oncology.

Something looks off?
Open jobs at Abcuro
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.